This is a great option for those who are looking to promote a steady and improved release of GH to get the benefits of increases in growth hormone and subsequently Insulin Like Growth Factor -1 (IGF-1) with almost no side effects. This therapy is effectively used for anti-aging purposes as well as those with inflammatory conditions, disease or those who have low IGF-1 levels.
Example 1 - Night Time Injection (recommended) ◦Ensure you do not eat or drink anything containing calories within three (3) hours of going to bed (with the exception of water, diet sodas, coffee/tea with artificial sweeteners). ◦Take your HGH Frag 176-191 injection just before getting into bed and your body will therefore be burning stored fat for the duration of your sleep. ◦If possible, do some cardio first thing in the morning and wait as long as possible before having breakfast to allow the fat burning to continue throughout the morning/day.
After the commencement of active treatment, 78.7% of subjects experienced at least one AE, with the incidence ranging from 75.6% to 83.2% across all treatment groups (83.2% placebo group; 75.6% 0.25 mg AOD9604 group). There was a high incidence of infections and infestations (46.8%, mainly nasopharyngitis, 17.1%), nervous system disorders (30.1%, mainly headache, 25.9%), musculo-skeletal and connective tissue disorders (25.5%, mainly back pain, 8.2%), and gastrointestinal disorders (22.9%, mainly diarrhea, 7.8%). Although the percentage of subjects experiencing AEs in these body systems is higher than in the run-in period there was no obvious pattern with respect to treatment received, suggesting that the increase was likely due to the longer period of assessment in the active treatment phase.

The biggest negative, and this is a big one, is that AOD9604 has undergone very rigorous scientific testing, and has been found to have no effect in humans (3). When AOD9604 was first developed, it showed significant promise as a weight loss treatment. A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis, or fat burning (5). Subsequent studies in obese mice and rats attempted to show that the peptide works to burn fat in the same way as human growth hormone, but found that this was not the case, meaning that the fact this peptide resembled hGH was meaningless. Scientists were unable to determine how this peptide was working in mice (6).
AOD9604, a synthetic fragment of hGH consisting of the amino acid residues 177–191 with the addition of a tyrosine residue to the N-terminus was prepared with solid-phase synthesis procedure and purified with reverse-phase HPLC methodology in our laboratories (13). The structure of the peptide analog was verified with mass spectrometry and amino acid analysis. The hGH was a gift of Professor Michael Waters (University of Queensland, Brisbane, Australia). BRL37344 (β3-AR agonist) was a gift from Dr. Jon Arch (SmithKline Beecham, Harlow, UK).
Improved glucose metabolism after RYGB and sleeve gastrectomy involves several mechanisms: early increased hepatic insulin sensitivity, resulting from reduced liver fat content in response to the postoperative caloric restriction, improved beta-cell function mediated by exaggerated postprandial GLP-1 secretion; as demonstrated by relapse of impaired glucose tolerance in studies blocking the GLP-1 receptor by exendin 9–39, and later after major weight loss increased peripheral insulin sensitivity. Gut hormone secretion changes towards a more anorectic profile and is likely important for less caloric intake and weight loss.
Improved glucose metabolism after RYGB and sleeve gastrectomy involves several mechanisms: early increased hepatic insulin sensitivity, resulting from reduced liver fat content in response to the postoperative caloric restriction, improved beta-cell function mediated by exaggerated postprandial GLP-1 secretion; as demonstrated by relapse of impaired glucose tolerance in studies blocking the GLP-1 receptor by exendin 9–39, and later after major weight loss increased peripheral insulin sensitivity. Gut hormone secretion changes towards a more anorectic profile and is likely important for less caloric intake and weight loss.
Kor Naturals Fat Burner For Men acts as a powerful thermogenic weight-loss supplement, using all natural ingredients that focus on improving metabolic function, preventing hunger cravings, increasing energy, and promoting the natural metabolism of calories and fat. Users love the chemical-free formula, and how simple it is to add this fat burner into your diet routine. Ingredients like Garcinia Cambogia, B Vitamins, and enhanced Caffeine are scientifically researched and proven to help you reach your weight loss goals. On top of being a great fat burning formula, Kor Naturals gives you a 90 day money back guarantee of 100% satisfaction!
As in the previous study there were no clinically relevant changes observed in safety laboratory parameters 24 hours following administration of AOD9604 or placebo. Similarly, there were no clinically relevant changes in vital signs (blood pressure, radial pulse rate and temperature) or ECGs recorded at any of the scheduled time points up to 24 hours post dose. There were no significant changes in glucose or IGF-1 levels following AOD9604 treatment compared with placebo.

Whilst AOD9604 is not approved by the Australian TGA, it can be legally obtained on a doctor's prescription and dispensed by a compounding pharmacy (2). This is true of many experimental substances, but it does big favours for the reputation of AOD9604, giving the impression that, like other drugs issued by the medical profession, it is an efficacious and high quality product. These reasons, when considered together, give a powerful impression that peptides are highly effective – they wouldn't ban them for no reason, would they?
Application would result in all current OTC paracetamol/ phenylephrine products being up-scheduled to S3. Applicant’s justification for changing current combination products from exempt or S2 to S3 is on theoretical basis only, and no evidence provided of clinical risk. Pharmacokinetic study found that co-administration of paracetamol with phenylephrine increased plasma phenylephrine levels - applicant says this has potential for cardiac safety risk in susceptible patients.

Ghrelin and GH secretagogues, including GH-releasing peptide (GHRP)-6, stimulate food intake and adiposity. Because insulin modulates the hypothalamic response to GH secretagogues and acts synergistically with ghrelin on lipogenesis in vitro, we analyzed whether insulin plays a role in the metabolic effects of GHRP-6 in vivo. Streptozotocin-induced diabetic rats received saline, GHRP-6, insulin, or insulin plus GHRP-6 once daily for 8 wk. Rats receiving saline suffered hyperglycemia, hyperphagia, polydipsia, and weight loss. Insulin, but not GHRP-6, improved these parameters (P < 0.001 for all), as well as the diabetes-induced increase in hypothalamic mRNA levels of neuropeptide Y and agouti-related peptide and decrease in proopiomelanocortin. Cocaine amphetamine-related transcript mRNA levels were also reduced in diabetic rats, with GHRP-6 inducing a further decrease (P < 0.03) and insulin an increase. Diabetic rats receiving insulin plus GHRP-6 gained more weight and had increased epididymal fat mass and serum leptin levels compared with all other groups (P < 0.001). In epididymal adipose tissue, diabetic rats injected with saline had smaller adipocytes (P < 0.001), decreased fatty acid synthase (FAS; P < 0.001), and glucose transporter-4 (P < 0.001) and increased hormone sensitive lipase (P < 0.001) and proliferator-activated receptor-gamma mRNA levels (P < 0.01). Insulin normalized these parameters to control values. GHRP-6 treatment increased FAS and glucose transporter-4 gene expression and potentiated insulin's effect on epididymal fat mass, adipocyte size (P < 0.001), FAS (P < 0.001), and glucose transporter-4 (P < 0.05). In conclusion, GHRP-6 and insulin exert an additive effect on weight gain and visceral fat mass accrual in diabetic rats, indicating that some of GHRP-6's metabolic effects depend on the insulin/glucose status.
By increasing our own growth hormone levels (which normally decrease as we age), there is an increase in protein synthesis which subsequently stimulates muscle growth.  It leads to an increase in muscle mass, an increase in fat metabolism (fat loss), and increase in physical strength.  It is also helpful in skin ageing, and effective in reducing wrinkles.
Echocardiographic measurements obtained at pre‐ and post‐bypass visits are outlined in Table 2. Due to limitations in scanning windows and poor image quality, interpretable echocardiograms were obtained in 12 of 15 patients. Transmitral E increased from 76±19 cm/s at pre‐bypass to 83±19 cm/s at the post‐bypass surgery visit while no significant increase was noted in transmitral A. The mean intra‐individual change in transmitral E was 15 cm/s, with 95% confidence interval 3 to 26 cm/s. The increases in transmitral E were significant for the effects of saline (P=0.005) and surgery (P=0.002). There was also a significant increase in the early diastolic mitral annular velocity e′ (P=0.02 for effect of surgery). However, the E/e′ ratio did not change after surgery (Table 2). Left atrial diameter showed a trend towards decrease at the post‐bypass surgery visit (P=0.3).
CJC-1295 and Mod GRF 1-29 are administered in micrograms (mcg) rather than milligrams (mg) – the unit of administration of other steroids and performance-enhancing drugs. It has also been found that a 100mcg dose is enough to fully saturate the receptors in the anterior pituitary. This is called the saturation dose. After a dose of 100mcg has been administered, the subsequent dosages will achieve only half the effect.
The four groups showed different gross morphological damage and histopathological changes in the cartilage of the lateral part of the femoral condyle (Figure 3). Complete disorganization of articular cartilage with apparent cloning of chondrocytes in the transitional and radial zones was evident in Group 1 (Figures 3-A,E,I). Abnormal gross morphological and histopathological changes such as fibrillated and irregular cartilage surfaces, disappearance of surface-layer cells, and slightly diffused cell growth in the transitional and radial zones were observed in Group 2 (Figures 3-B,F,J). Erosion of the articular cartilage, cleft, and cell cloning in the transitional and radial zones were noted in Group 3 (Figures 3-C,G,K). Softening of articular cartilage and surface irregularities were noted in Group 4 (Figures 3-D,H,L).
PCR amplification was carried out on cDNA equivalent to 100 ng of starting mRNA using the following murine oligonucleotide primers (expected and observed PCR product size): β3-AR forward, 5′-TCTAGTTCCCAGCGGAGTTTTCATCG-3′; (234 bp) reverse, 5′-CGCGCACCTTCATAGCCATCAAACC-3′; β-actin forward, 5′-ATCCTGCGTCTGGACCTGGCTG-3′; (559 bp) reverse, 5′-CCTGCTTGCTGATCCACATCTGCTG-3′.
In a statement to Fairfax Media on Thursday, Calzada Ltd said: ''The US generally recognised as safe 'GRAS' status is being explored as another viable commercial path for the company to pursue to potentially derive early revenue. Whilst AOD-9604 was not successful in human trials aimed at obesity, the Company believes there is sufficient efficacy data to enable a potential food, drink or dietary supplement product to be successfully marketed in the US.''
Ipamorelin is very similar to the growth hormone releasing peptides (GHRPs) GHRP 2 and GHRP 6 in that it mimics ghrelin (the hunger hormone) and targets a specific HGH pulse. However, unlike other GHRPs, this peptide doesn’t affect the release of cortisol, acetylcholine, prolactin and aldosterone thereby minimizing side effects experienced with other GH therapies, such as increased hunger. Because there are virtually no negative side effects, Ipamorelin can be prescribed more aggressively and more frequently than other therapies without the risk of elevated cortisol and acetylcholine blood plasma levels. This helps optimize HGH levels for a longer period of time, leading to more successful health outcomes.

An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.


A total of 18 patients (3.6%) reported at least one SAE. The distribution of SAEs was similar among all treatment groups (Table 2). The most common SAEs reported were in the injury, poisoning and procedural complications body system class (6 patients, 1.2%). The others were general disorders and administration site conditions (2 patients; 0.4%), infections and infestations (2 patients; 0.4%), musculo-skeletal and connective tissue disorders (2 patients; 0.4%), and vascular disorders (2 patients; 0.4%).
AOD aka Advanced Obesity Drug., Fat Loss Peptide AOD 9604 consists of the get along 15 amino acids of the human wealth hormone molecule. The considerable thing close but no cigar AOD 9604 is it has no doom on accomplishment or insulin resistance. With an fine safety sketch of minimal side chattels personal, AOD 9604 has been proven more effective than consequently occuring Growth Hormone at fresh the collapse of fat. Studies have proven its efficiency to reduce biggest slice of the cake full, by way of explanation in the abdominal area.
Great, I just filled a script for ipamorelin yesterday and it will ship today. This will be the 1st time use. I’m 41, 6’1 210 pretty fit, recently had an acl replaced 1.5 yr ago and a wrist surgery, and have some lower back and shoulder pain that I ignore. How long/short could I use this to feel any rebuilding effect. I certainly don’t want bloat, or cancer. I might be able to cancel the order 1st thing this a.m. Thanks.
A total number of 207 AEs were reported by 36/36 subjects. All but one was of mild to moderate intensity (placebo-treated subject, soft tissue injury to left shoulder, unrelated to study treatment). No SAE occurred during the 7-day treatment and the 7-day follow-up time. The rate as well as the AE profile was comparable in the 9 mg, 27 mg AOD9604 and the placebo group. There was no observable trend between treatment groups with respect to the incidence of certain AEs, however subjects who received 54 mg AOD9604 experienced a greater number of headaches, diarrhea and flatulence.
Time line of collagenase, saline, HA and AOD9604 injection. Collagenase (0.25 mg) was injected in right knee twice on day 1 and 4, respectively. Normal saline 0.6 ml (group 1), HA 6 mg (group 2), AOD9604 0.25 mg (group 3), and AOD9604 0.25mg with HA 6 mg (group 4) were injected in the right knee at 4 weeks after the first collagenase injection. All rabbits were euthanized by CO inhalation at 4 weeks after injection of 4 different solutions.
I'm using 100mcg 6am-12pm-6pm(3xday) HGH Fragment 176-191 and the last shot around 6pm taking 100mcg of GHRP-6 from SouthernResearchCo, I gotta brag on their quality and value there's no others on the same level (IMO)! I dropped 10-15lbs as soon as I started too! NO catabolic or any adverse effects. Well, I did get head aches and super shits when I first began but by wk2 I notice nothing and feel so great! My tummy looks so much better too, my wifes all jealous as hell n gets mad saying she wont compliment it cuz I use drugs to attain leanness lol Fk it
Obesity affects as many as one in five adults in developed countries. Metabolic estimates that the potential worldwide market for effective obesity drugs is as much as $20 billion, far more than the current market of $1.5 billion. This is partly due to the potential need for chronically obese people to take obesity drugs such as AOD9604 and also because patients are put off using currently available drugs because of their marginal efficacy or side-effects.
AOD is a peptide 15 amino acids long which mimics a small portion of the growth hormone that has the fat reducing effects (increases fat metabolism). It works by mimicking the way natural growth hormone regulates fat metabolism but without the adverse effects on blood sugar and growth that is seen if unmodified growth hormone is given. It stimulates lipolysis (break down of fat) and inhibits lipogenesis (non fat food being stored in the body as fat).
As simple and basic as it is, eating less calories is much harder in practice than it sounds. Ask anyone who has ever gone on a diet before! Everyone knows if you want to lose weight, you need to eat less. It’s the first step of any legitimate diet and fitness program, but how much less, and what to eat remains a mystery to many dieters. Or, the results don’t come quickly enough and the dieter gives up before real results are experienced.
Cerebrolysin: A mixture of peptides extracted from pig brain that supports the development and function of nerve cells, cerebrolysin can be used to treat Alzheimer’s disease and vascular dementia but because the drug needs to be injected daily, it doesn’t have a clear benefit over existing oral medication. It’s not known to have any major side effects. In sports, cerebrolysin used to enhance mental function and “defog” the brain, although there is no good evidence that it has any effect in healthy individuals. It’s not currently listed as banned under WADA, either directly or via similarity of mechanism to banned peptides.
In vitro studies by Metabolic Collaborators showed that AOD9604 enhances the differentiation of adipose mesenchymal stem cells into bone, promotes proteoglycan and collagen production in isolated bovine chondrocytes, and promotes differentiation of myoblasts into C2C12 cells. These effects induced by AOD9604 are similar to those required for the repair of bone, cartilage, and muscle, all of which are affected in OA. To the best of our knowledge, no study has compared the effects of GH and HA intra-articular injections on OA. A previous study showed the effects of intra-articular GH injection on articulophyseal cartilage regeneration in the knees of rabbits [9]. Our study showed that the groups that received AOD9604 or HA injection had better outcomes in terms of morphological and histolopathological findings, as well as a lowered duration of lameness than the group that received saline injections, although there are no significant differences between the two groups. In addition, our study revealed that the groups that received combined injections of AOD9604 and HA showed better outcomes than the groups that received AOD9604 or HA alone. The apparently synergistic effect of combined injections is thought to indicate that intra-articular injection of HA may have a chondrocyte-protective role, and the AOD9604 could help recapitulate the developmental cascades which regrows a segment of the articular cartilage in a joint. Our results are consistent with those of a previous study [8] that combined the injection of HA with recombinant human GH and found that the combination is more effective than HA injection alone.
I was using MT II while using the 1st vial and lost 14 lbs in 10 days. Had to fly to Pittsburgh for a couple days and started 2nd vial with no MT II and dropped 8 more. I weighed yesterday upon completion of the 2nd vial with shoes and clothes on. Was very pleased with the results. I did a cycle of T3 prior to the frag and didnt do near as well and was fighting muscle loss, felt like crap ect.. Will be purchasing more, I use Southern Research on the peptides.
OxySelect Pink is an advanced thermogenic and is the only diet pill specifically formulated to enhance the curves of a woman’s body. While other products contain stimulants and huge quantities of dubious fillers and preservatives, OxySelect Pink uses clinically-tested, all-natural extracts designed to help you lose weight. OxySelect Pink is one of the best choices for women looking to get leaner.

This particular peptide offers therapeutic benefits similar to those of hGH. CJC 1295 is a growth hormone releasing hormone (GHRH) analogue. In other words, it is a molecule that serves the same purpose as does GHRH—the hormone that stimulates the anterior pituitary to release hGH. However, unlike GHRH, which has a half-life of only minutes after IV administration, CJC 1295 is able to remain active in the body for extended periods due to its ability to bind to a protein in the blood known as albumin and avoid degradation by various enzymes. CJC 1295 increases an important growth factor, IGF-1, in addition to hGH, leading to fat loss, lean muscle growth, and enhanced sleep.
The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.

From this study it appears that the β3-AR is an important contributor to the effects observed on body weight in obese mice treated with AOD9604 and hGH. To determine whether theβ 3-AR is partly responsible for this effect, we examined the effects of AOD9604 and hGH in theβ 3-KO mouse. The β3-KO mouse is not grossly obese, but female mice have increased fat depots (21) and the mice do develop late-onset obesity (Summers, R. J., personal communication). AOD9604 and hGH increased body mass and decreased BAT mass in the WT strain but had no effect in the KO animals. In WT mice, plasma glycerol was increased in response to AOD9604 and hGH treatment (4 wk). However, in the KO mice, only hGH resulted in increased levels of glycerol in the KO mice, and this effect was significantly less than that observed in the WT mice. This suggests that the regulation of the β3-AR is essential in the ability of AOD9604 and hGH to mediate chronic effects on lipolysis and fat mass reduction.

Results: AOD9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD9604.


Australian owned and operated., Peptide Clinics is fully licensed and registered with our offices located in Sydney, NSW, Australia. Specialising in the production of dr approved, clinical grade peptides, Peptide Clinics Australia guarantees optimal purity and potency of their peptide supplements. Our peptide treatments each come with a Certificate of Analysis, confirming the absence of contaminants. Our online gateway grants you a secure and confidential access to buy peptide supplements online in Australia coupled with expert medical guidance in their safe and efficient use. Our licensed Dr is a renowned expert in his field of anti-ageing, longevity and sports medicine. His supervision and specialisation in peptide supplementation significantly benefit each Peptide Clinic patient in Australia.
×